-

$undefined

N/A

(N/A)

REGULUS THERAPEUTICS INC NasdaqCM:RGLS Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. The company has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc. to develop, manufacture, and commercialize products covered by the licensed patent rights for use in microRNA compounds. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Location: 4224 Campus Point Court, San Diego, CA, 92121, United States | Website: https://www.regulusrx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

485.8M

Cash

65.37M

Avg Qtr Burn

-10.89M

Short % of Float

3.31%

Insider Ownership

2.69%

Institutional Own.

82.87%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date